BioWorld

Feb. 23, 2006

Axcan: Functional Dyspepsia Drug Fails In Phase III Trial

Axcan Pharma Inc.’s ITAX for functional dyspepsia fizzled in Phase III, but the company said it will continue to work with the compound in other indications such as diabetic gastropathy. (BioWorld Today) Read More

PolyMedix Completes Reverse Merger, Closes $21.2M PIPE

Mad Cow Miscreant Necessary For Blood, Neural Self-Renewal

Cleveland BioLabs Files $14M IPO For Radiation Protection

CombinatoRx Halts Psoriasis Drug After Its Phase II Failure

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

European Commission floats multiple fixes for MDR, IVDR

BioWorld MedTech

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...

Decorative scales of justice in a courtroom

DOJ arrests shed light on Medicare skin substitute controversy

BioWorld MedTech

Much has been made of the recent skyrocketing of Medicare spending on skin substitutes, but a new enforcement action by the U.S. Department of Justice might help...